Regentis Biomaterials Ltd (RGNT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-1997 | 12-1996 | 09-1996 | 06-1996 | 03-1996 | |
| Assets | |||||
| Current Assets | |||||
| Other current assets | 90 | 100 | 76 | 80 | 120 |
| TOTAL | $90 | $100 | $76 | $80 | $120 |
| Non-Current Assets | |||||
| PPE Net | N/A | N/A | 12,618 | N/A | N/A |
| Investments And Advances | 280 | 260 | 0 | 0 | 0 |
| Other Non-Current Assets | 2,810 | 2,230 | 1,398 | 540 | 450 |
| TOTAL | $3,090 | $2,490 | $14,016 | $540 | $450 |
| Total Assets | $3,180 | $2,590 | $14,092 | $620 | $570 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | 150 | 140 | 72 | 70 | 60 |
| Accounts payable and accrued liabilities | 0 | 0 | 1,443 | 0 | 0 |
| Accrued Expenses | 380 | 390 | 39 | 40 | 40 |
| TOTAL | $530 | $530 | $1,554 | $110 | $100 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 420 | 470 | 461 | 420 | 330 |
| TOTAL | $420 | $470 | $461 | $420 | $330 |
| Total Liabilities | $950 | $1,000 | $2,015 | $530 | $430 |
| Shareholders' Equity | |||||
| Common Shares | 10,800 | 10,800 | 10,759 | 10,750 | 10,750 |
| TOTAL | $10,800 | $10,800 | $10,759 | $10,750 | $10,750 |
| Total Liabilities And Equity | $11,750 | $11,800 | $12,774 | $11,280 | $11,180 |